Literature DB >> 33558335

miR-31 Displays Subtype Specificity in Lung Cancer.

Mackenzie L Davenport1, John B Echols1, Austin D Silva1, Joshua C Anderson2, Philip Owens3,4, Clayton Yates5, Qing Wei6, Shuko Harada6, Douglas R Hurst6, Mick D Edmonds7.   

Abstract

miRNA rarely possess pan-oncogenic or tumor-suppressive properties. Most miRNAs function under tissue-specific contexts, acting as either tumor suppressors in one tissue, promoting oncogenesis in another, or having no apparent role in the regulation of processes associated with the hallmarks of cancer. What has been less clear is the role of miRNAs within cell types of the same tissue and the ability within each cell type to contribute to oncogenesis. In this study, we characterize the role of one such tissue-specific miRNA, miR-31, recently identified as the most oncogenic miRNA in lung adenocarcinoma, across the histologic spectrum of human lung cancer. Compared with normal lung tissue, miR-31 was overexpressed in patient lung adenocarcinoma, squamous cell carcinoma, and large-cell neuroendocrine carcinoma, but not small-cell carcinoma or carcinoids. miR-31 promoted tumor growth in mice of xenografted human adenocarcinoma and squamous cell carcinoma cell lines, but not in large- or small-cell carcinoma lines. While miR-31 did not promote primary tumor growth of large- and small-cell carcinoma, it did promote spontaneous metastasis. Mechanistically, miR-31 altered distinct cellular signaling programs within each histologic subtype, resulting in distinct phenotypic differences. This is the first report distinguishing diverse functional roles for this miRNA across the spectrum of lung cancers and suggests that miR-31 has broad clinical value in human lung malignancy. SIGNIFICANCE: These findings demonstrate the oncogenic properties of miR-31 in specific subtypes of lung cancer and highlight it as a potential therapeutic target in these subtypes. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/8/1942/F1.large.jpg. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33558335      PMCID: PMC8137562          DOI: 10.1158/0008-5472.CAN-20-2769

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  62 in total

Review 1.  The diverse role of miR-31 in regulating cancer associated phenotypes.

Authors:  Eeva M Laurila; Anne Kallioniemi
Journal:  Genes Chromosomes Cancer       Date:  2013-09-02       Impact factor: 5.006

2.  Oxidative stress associates with aggressiveness in lung large-cell carcinoma.

Authors:  Leonardo Lisboa da Motta; Marco Antonio De Bastiani; Fernanda Stapenhorst; Fábio Klamt
Journal:  Tumour Biol       Date:  2015-02-01

3.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

4.  Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries.

Authors:  Jeffrey O Bush; Philippe Soriano
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

5.  EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Authors:  Katherine R Amato; Shan Wang; Li Tan; Andrew K Hastings; Wenqiang Song; Christine M Lovly; Catherine B Meador; Fei Ye; Pengcheng Lu; Justin M Balko; Daniel C Colvin; Justin M Cates; William Pao; Nathanael S Gray; Jin Chen
Journal:  Cancer Res       Date:  2016-01-07       Impact factor: 12.701

6.  Presenilin-dependent intramembrane cleavage of ephrin-B1.

Authors:  Taisuke Tomita; Sayaka Tanaka; Yuichi Morohashi; Takeshi Iwatsubo
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

7.  Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2.

Authors:  Min-Hui Yang; Jiang Yu; Na Chen; Xiao-Yan Wang; Xiang-Yu Liu; Shuang Wang; Yan-Qing Ding
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

8.  An Unusually Aggressive Large Cell Carcinoma of the Lung: Undiagnosed until Autopsy.

Authors:  Kartikeya Rajdev; Abdul Hasan Siddiqui; Uroosa Ibrahim; Prateek Patibandla; Tahir Khan; Dany El-Sayegh
Journal:  Cureus       Date:  2018-02-19

9.  Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.

Authors:  Oliver A Kent; Joshua T Mendell; Robert Rottapel
Journal:  Mol Cancer Res       Date:  2016-01-08       Impact factor: 5.852

Review 10.  Established, emerging and elusive molecular targets in the treatment of lung cancer.

Authors:  Jean-Nicolas Gallant; Christine M Lovly
Journal:  J Pathol       Date:  2018-02-14       Impact factor: 9.883

View more
  6 in total

1.  MiR-186 Suppressed Growth, Migration, and Invasion of Lung Adenocarcinoma Cells via Targeting Dicer1.

Authors:  Juan Wang; Yi Zhang; Fanghong Ge
Journal:  J Oncol       Date:  2021-11-11       Impact factor: 4.375

2.  The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells.

Authors:  Marianna Gallo; Marianeve Carotenuto; Daniela Frezzetti; Rosa Camerlingo; Cristin Roma; Francesca Bergantino; Nicola Normanno; Antonella De Luca
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

Review 3.  MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Zuha Imtiyaz; Muneeb U Rehman; Rana M Alsaffar; Naveed Nazir Shah; Sultan Alshehri; Mohammed M Ghoneim; Syed Sarim Imam
Journal:  Diagnostics (Basel)       Date:  2022-07-01

4.  Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma.

Authors:  Chia-Hsin Liu; Shu-Hsuan Liu; Yo-Liang Lai; Yi-Chun Cho; Fang-Hsin Chen; Li-Jie Lin; Pei-Hua Peng; Chia-Yang Li; Shu-Chi Wang; Ji-Lin Chen; Heng-Hsiung Wu; Min-Zu Wu; Yuh-Pyng Sher; Wei-Chung Cheng; Kai-Wen Hsu
Journal:  Comput Struct Biotechnol J       Date:  2022-08-22       Impact factor: 6.155

Review 5.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

6.  Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer.

Authors:  Mona Ahmed Abbas; Ibrahim El Tantawy El Sayed; Azza Mohamed Kamel Abdu-Allah; Abul Kalam; Abdullah G Al-Sehemi; Omar A Al-Hartomy; Maha Salah Abd El-Rahman
Journal:  Noncoding RNA Res       Date:  2022-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.